Multi-drug resistant HIV-1

Journal of Infection

Volumn 41, Issue 1, 2000, Pages 5-11

  Omrani, A S ^a   Pillay, D ^b  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALANINE; AMPRENAVIR; ANTIRETROVIRUS AGENT; ASPARAGINE; ASPARTIC ACID; CYSTEINE; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; GLUTAMIC ACID; GLYCINE; HISTIDINE; INDINAVIR; ISOLEUCINE; LAMIVUDINE; LEUCINE; LYSINE; METHIONINE; NELFINAVIR; NEVIRAPINE; PHENYLALANINE; PROLINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; CONTROLLED STUDY; CROSS RESISTANCE; DRUG BINDING; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; REVIEW; VIRUS GENE; VIRUS REPLICATION;

EID: 0033836451     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1053/jinf.2000.0702     Document Type: Review

References (94)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators
2. Antiretroviral drug resistance testing in adults with HIV infection, implications for clinical management
3. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
4. The accuracy of reverse transcriptase from HIV-1
5. Selection of HIV-1 variants with wide cross-resistance to reverse transcriptase inhibitors during low-level escape to first line dual nucleoside therapy
6. How much adherence is enough? A prospective study of adherence to protease inhibitor therapy using MemsCaps (Abstract 92)
7. Intracellular phosphorylation of stavudine and lamivudine correlates with their antiviral activity in naive and zidovudine-experienced HIV-infected patients (Abstract 362)
8. Sanctuary sites in HIV-1 infection
9. Selection of antiretroviral resistance in the latent reservoir of human immunodeficiency virus type 1 during successful therapy (Abstract 238)
10. Distinct but related human immunodeficiency virus type 1 variant populations in genital secretions and blood
11. Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type-1-infected women receiving antiretroviral therapy (Abstract 679)
12. Multiple mutations in HIV-1 reverse transcriptase confer high level resistance to zidovudine (AZT)
13. Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture
14. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high level resistance to 3'-azido-3'-deoxythymidine
15. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase
16. Initial appearance of the 184lle variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase
17. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase
18. Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase
19. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture
20. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89
21. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine
22. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine monotherapy in a phase I clinical trial (ACTG 187): Comparison to patients receiving combination therapy with ATV and zidovudine
23. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
24. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents
25. L-743,726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase
26. Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266
27. HIV-1 Drug susceptibilities during therapy with delavirdine (DLV)+ZDV, DLV+DDI, or DLV+ZDV+DDI (Abstract 706)
28. A mutation in reverse transcriptase of bis (heteroaryl) piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors
29. Genetic correlates of in vivo viral resistance to the HIV-1 protease inhibitor indinavir
30. In vivo selection of HIV-1 variants with reduced susceptibility to the protease inhibitor L-735,524 and related compounds
31. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors
32. Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors
33. Ordered accumulation for mutation in HIV protease confers resistance to ritonavir
34. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538)
35. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease
36. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir
37. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations
38. In vitro resistance to human immunodeficiency virus type 1 proteinase inhibitor: Mutations, kinetics, and frequencies
39. Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959
40. In vitro selection and characterisation of human deficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease
41. Cross-resistance to amprenavir in PI-treated patients (Abstract 726)
42. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy
43. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides
44. Multiple dideoxynucleoside analogue-resistance (MddNR) HIV-1 strains isolated from patients from different European countries
45. Identification and Characterization of a novel multidrug resistance mutation (Q151L) in drug-naive HIV-1 seroconverters
46. The Multiple Nucleoside Analogue Resistance Mutations Confer Cross-Resistance to Abacavir (Abstract 113)
47. Prevalence of multinucleoside drug resistance among European HIV-1-infected patients receiving various combinations of nucleoside analogues
48. Phenotypic and molecular analysis of HIV-1 isolates prossessing 6 bp inserts in the reverse transcriptase gene that confer resistance to nucleoside analogues
49. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs
50. Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors
51. An amino acid deletion at codon 67 and a novel substitution T69G in the RT of HIV-1 confer multidrug resistance (Abstract 738)
52. Prevalence of multiple dideoxynucleoside analogue resistance in a multicentric cohort of HIV-1 Italian patients with virologic failure
53. Common, rare and new HIV-1 resistance profiles observed in routine clinical practice. A survey of over 5,000 isolates and the characterisation of a novel 3TC resistance mutational profile lacking 184V (Abstract 107)
54. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors
55. Highly drug-resistant HIV-1 isolates are cross-resistant to many of the current anti-HIV compounds in clinical development
56. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients
57. Efficacy of stavudine therapy after prior zidovudine therapy is inversely correlated with frequency of reverse transcriptase inhibitor resistance mutations and initial viral load
58. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine
59. Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy
60. Stavudine-based combination and monotherapy select for zidovudine resistance HIV-1 mutations in zidovudine-naive adults and in paediatric patients
61. Emergence of zidovudine resistance in HIV-positive patients receiving stavudine
62. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors
63. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors
64. RT gene mutations associated with resistance to efavirenz
65. 3'-azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors
66. Sequencing of non-nucleoside reverse transcriptase inhibitors based on specific mutational patterns fails to lower plasma HIV-RNA levels in persons extensively pre-treated with antiretrovirals who are failing virologically on nevirapine-containing antiretroviral regimens (Abstract 208)
67. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy
68. HIV and multidrug resistance
69. Prevalence of drug-resistant genotypes in heavily pretreated patients with current failure
70. Patterns of cross-resistance among protease inhibitors in over 1500 clinical HIV-1 isolates. Comparison of genotypic and phenotypic resistance profiles
71. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies
72. Limited efficacy of nelfinavir after failure of other protease inhibitors (Abstract 12281)
73. Cross-resistance to nelfinavir can be predicted by previous antiretroviral exposure in the absence of D30N mutation (Abstract 729)
74. ACTG 333: Antiviral effects of switching from saquinavir hard capsules (SQVhc) to saquinavir soft gelatin capsules (SQVsgc) vs. switching to indinavir (IDV) after prior saquinavir (Abstract 21)
75. Sexual transmission of an HIV-1 variant to multiple reverse transcriptase and protease inhibitors
76. Reverse transcriptase and protease gene analysis at the time of primary HIV-1 infection
77. Transmission of HIV-1 resistant to multiple reverse transcriptase and protease inhibitors
78. Transmission of dual and triple-class drug-resistant viral variants in primary/early HIV-1 infection (PHI) in Montreal (Abstract 567)
79. Virologic failure during combination therapy with CRIXIVAN and RT inhibitors is often associated with expression of resistance-associated mutations in RT only (Abstract 492)
80. Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: Association with therapy failure
81. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy
82. Impact of drug resistance mutations on virological response to salvage therapy
83. Lack of fitness of protease inhibitor-resistant HIV-1 in vivo (Abstract 4)
84. Relative fitness of efavirenz-resistant mutants of HIV-1
85. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy
86. Can resistance-associated loss of viral fitness explain discordant CD4 and plasma HIV RNA evolution following protease inhibitor failure?
87. Virologic and immunologic evaluation of structured treatment interruptions (STI) in patients experiencing long-term virologic failure (Abstract LB10)
88. Vertical transmission of an HIV-1 variant resistant to multiple reverse transcriptase and protease inhibitors (Abstract 266)
89. HIV-1 drug resistance in newly infected individuals
90. Reduced antiretroviral drug susceptibility among patients with primary HIV infection
91. HIV-1 primary transmitted mutations and HIV-1 subtyping in a cohort of individuals recently infected with HIV-1
92. Documentation of HIV-1 super-infection and acceleration of disease progression (Abstract LB2)
93. ABT-378/Ritonavir (ABT-387/r) suppresses HIV RNA to <400 copies/mL in 95% of treatment-naive patients and in 78% of PI-experienced patients at 36 weeks (Abstract LB-20)
94. Sixteen week analysis of heavily pre-treated patients receiving T-20 as a component of multi-drug salvage therapy (Abstract LB-18)